Manipulating the EphB4-ephrinB2 axis to reduce metastasis in HNSCC
Open Access
- 3 November 2024
- journal article
- research article
- Published by Springer Nature in Oncogene
- Vol. 44 (3) , 130-146
Abstract
The EphB4-ephrinB2 signaling axis has been heavily implicated in metastasis across numerous cancer types. Our emerging understanding of the dichotomous roles that EphB4 and ephrinB2 play in head and neck squamous cell carcinoma (HNSCC) poses a significant challenge to rational drug design. We find that EphB4 knockdown in cancer cells enhances metastasis in preclinical HNSCC models by augmenting immunosuppressive cells like T regulatory cells (Tregs) within the tumor microenvironment. EphB4 inhibition in cancer cells also amplifies their ability to metastasize through increased expression of genes associated with hallmark pathways of metastasis along with classical and non-classical epithelial-mesenchymal transition. In contrast, vascular ephrinB2 knockout coupled with radiation therapy (RT) enhances anti-tumor immunity, reduces Treg accumulation into the tumor, and decreases metastasis. Notably, targeting the EphB4-ephrinB2 signaling axis with the engineered ligands ephrinB2-Fc-His and Fc-TNYL-RAW-GS reduces local tumor growth and distant metastasis in a preclinical model of HNSCC. Our data suggests that targeted inhibition of vascular ephrinB2 while avoiding inhibition of EphB4 in cancer cells could be a promising strategy to mitigate HNSCC metastasis.Keywords
All Related Versions
Funding Information
- U.S. Department of Health & Human Services | National Institutes of Health (R01DE028529 (SDK), R01CA28465 (SDK), P50CA261605-01 (SDK), P30 DK063720, P30 DK063720)
- V Foundation for Cancer Research (V Foundation (SDK)
- U.S. Department of Health & Human Services | NIH | National Cancer Institute (F31 DE029997, F31 DE033887-01)
This publication has 122 references indexed in Scilit:
- Radiotherapy plus cetuximab or cisplatin in head and neck squamous cell carcinoma: an updated systematic review and meta-analysis of randomized controlled trialsEuropean Archives of Oto-Rhino-Laryngology, 2022
- Head and Neck Squamous Cell Carcinoma: Risk Factors, Molecular Alterations, Immunology and Peptide VaccinesInternational Journal of Peptide Research and Therapeutics, 2021
- The effects of ephrinB2 signaling on proliferation and invasion in glioblastoma multiformeMolecular Carcinogenesis, 2020
- β‐catenin deficiency in hepatocytes aggravates hepatocarcinogenesis driven by oncogenic β‐catenin and METHepatology, 2017
- Distant metastases in head and neck cancerHead & Neck, 2017
- Overexpression of EphB4, EphrinB2, and epidermal growth factor receptor in papillary thyroid carcinoma: A pilot studyHead & Neck, 2014
- The role of tenascin-C in tissue injury and tumorigenesisJournal of Cell Communication and Signaling, 2009
- Prolonged expression of a lysosomal enzyme in mouse liver after Sleeping Beauty transposon‐mediated gene delivery: implications for non‐viral gene therapy of mucopolysaccharidosesThe Journal of Gene Medicine, 2007
- The Association Between Elevated EphB4 Expression, Smoking Status, and Advanced-Stage Disease in Patients With Head and Neck Squamous Cell CarcinomaJAMA Otolaryngology–Head & Neck Surgery, 2006
- EphB4 provides survival advantage to squamous cell carcinoma of the head and neckInternational Journal of Cancer, 2006